VBL Therapeutics VBLT Stock

Vascular Biogenics Ltd (NASDAQ: VBLT) is running for the top in the market this morning, and for good reason. The company announced positive data, exciting investors. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VBLT Announces Positive Data

In the press release, VBL Therapeutics presented data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis. This is the first time the company is announced data of this kind. The company said that it would be presenting the data at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting.

VBLT explained that the data show that the treatment inhibited the migration of monocytes isolated from all MS patients included in the study by up to 97%. This result was consistent regardless of disease severity, gender or active treatment.

Importantly, the company realized activity in primary progressive and secondary progressive patients with high Expanded Disability Status Scale score of 5.5-6.5.

In a statement, Itzhak Mendel, Ph.D., Immunology Director of VBLT, had the following to offer:

We believe our antibodies open up a completely novel mechanism for potential treatment of MS, through blocking the accumulation of monocytes/macrophages in the central nervous system. This mechanism is differentiated from the existing available treatments, which mostly target T and B cells and therefore, it is not surprising that our antibodies showed activity on top of any patient active therapy. Backed up by strong preclinical results, these first patient-driven proof-of-concept data reinforce the therapeutic potential of our MOSPD2 program.

This Is Huge News

Any time positive data is released, the news is positive, but this particular news is even more compelling. MS is a serious condition for which there are no currently approved cures and few effective treatments.

The data suggests that the company’s anti-MOSPD2 mAbs have the potential to be an effective therapeutic option for patients with MS. Moreover, results were similar regardless of disease severity or progression, or prior treatments, suggesting that the treatment may be effective for the entire MS patient population.

Should this be the case, it’s a massive opportunity.

By 2026, it is expected that the MS therapeutics market will climb to be worth around $28 billion. Should VBLT be working on what may prove to be the most effective treatment option in this massive market, the drug could become a blockbuster. Not bad for a company that currently trades with a $60 million market cap.

All in all, VBLT stock is one to watch.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.